tm logo
ABSIEVE
Live/Registered
REGISTERED

on 15 Aug 2017

Last Applicant/ Owned by

Teslova 3

Plzen

CZ

30100

Serial Number

86970797 filed on 11th Apr 2016

Registration Number

5263476 registered on 15th Aug 2017

in the Principal Register

Correspondent Address

Karen L. Elbing

CLARK & ELBING LLP

101 FEDERAL STREET, 15TH FLOOR

BOSTON,MA 02110

Filing Basis

No Filing Basis

Disclaimer

NO DATA

ABSIEVE

Scientific and technological services and research projects for the preparation of peptide and antibody libraries, and for identification and characterization of binding molecules, namely, scientific research and analysis in the field of antibody discovery; scientific and technological services and research projects for the preparation, identification and characterisation of peptides and antibodieRead More

Classification Information


Class [042]
Computer & Software Services & Scientific Services


Scientific and technological services and research projects for the preparation of peptide and antibody libraries, and for identification and characterization of binding molecules, namely, scientific research and analysis in the field of antibody discovery; scientific and technological services and research projects for the preparation, identification and characterisation of peptides and antibodies, namely, scientific research and analysis in the field of antibody discovery; scientific and technological services and research projects for the preparation and identification of recombinant antibodies, single-chain antibodies, diabodies, tandabs, flexibodies, triabodies, tetrabodies, bivalent antibodies, multivalent antibodies, whole immunoglobulins, and antibody fragments, in particular Fab and scFv fragments, and of nucleic acid sequences coding for these molecules, namely, scientific research and analysis in the field of antibody discovery; scientific and technological services and research projects in relation to antibody discovery, namely, scientific research and analysis in the field of antibody research and drug design; scientific and technological services and research projects in relation to screening of natural, engineered and immunized libraries, namely, scientific research and analysis in the field of antibody discovery; scientific and technological services and research projects in relation to screening of antibody libraries, namely, scientific research and analysis in the field of antibody discovery; scientific and technological services and research projects in relation to phage display, phage panning and yeast display vectors, namely, scientific research and analysis in the field of antibody discovery; scientific and technological services and research projects in relation to next-generation yeast display and antibody selection process, namely, scientific research and analysis in the field of antibody discovery; scientific and technological services and research projects in relation to the upstream enrichment of target-specific candidates and batch cloning into yeast-display vectors, namely, scientific research and analysis in the field of antibody discovery; scientific and technological services in relation to drug discovery by high throughput screen and antibody delivery for therapeutic application, namely, scientific research and analysis in the field of antibody research and drug design

Mark Details


Serial Number

No 86970797

Mark Type

No Service Mark

Attorney Docket Number

No 50125-T82001

44D Filed

Yes

44D Current

No

44E filed

No

44E Current

Yes

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Legal History


Show more

Status DateAction Taken
08th Feb 2024TEAS SECTION 8 & 15 RECEIVED
15th Aug 2022COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
15th Aug 2017REGISTERED-PRINCIPAL REGISTER
30th May 2017PUBLISHED FOR OPPOSITION
30th May 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10th May 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
25th Apr 2017LAW OFFICE PUBLICATION REVIEW COMPLETED
17th Apr 2017APPROVED FOR PUB - PRINCIPAL REGISTER
13th Apr 2017TEAS/EMAIL CORRESPONDENCE ENTERED
12th Apr 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED